Q-omics provides the consensus-scored ZNF117 profile across patient tissues and cancer cell-line models. ZNF117 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF117 is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF117 RNA expression shows 19,786 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where ZNF117 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF117 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF117 survival associations across molecular data types. ZNF117 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF117 RNA expression–survival associations across cancer types. High ZNF117 expression shows unfavorable associations in KIRC, STAD, UVM, KICH and CESC, but favorable associations in THCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF117 RNA expression.
This table summarizes ZNF117 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF117. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF117 shows higher tumor expression in LIHC, LUAD, BLCA, STAD, COAD and CHOL. The LIHC box plot shows higher ZNF117 RNA expression in tumor versus normal tissue (log2 FC = +0.780, t-test p < 0.001).
This table shows molecular features associated with ZNF117 in patient tissues and cancer cell lines. In patient samples, ZNF117 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF117 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
